Simple and rapid hplc method for the determination of alfuzosin in human plasma

Jordan Journal of Pharmaceutical Sciences

Volumn 3, Issue 1, 2010, Pages 25-36

  Shakya, Ashok K ^a   Arafat, Tawfiq A ^b   Abuawaad, Ahmad ^b   Al Hroub, Hamza ^b   Melhim, Munther ^b  

^a AL AHLIYYA AMMAN UNIVERSITY   (Jordan)

^b Jordan Center for Pharmaceutical Research Amman   (Jordan)

Author keywords

Alfuzosin; Assay; Hplc; Plasma

Indexed keywords

ALFUZOSIN; ATENOLOL;

ARTICLE; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; PARTICLE SIZE; QUALITY CONTROL; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

EID: 77953461271     PISSN: 19957157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Cavero I., Lefevre-Borg, F. and Manoury P. Alfuzosin (SL77.499), A new Antihypertensive agent with a peripheral site of action: 1. In vivo pharmacological studies. Br. J. Pharmacol. Suppl. 1984:13P.
2. Cavero I, Lefevre-Borg F. and Manoury P., Fed. Proc., Fed. Am. Soc. Exp. Biol. 1984; 43: p. 3 abstract No. 2627.
3. Guinebault P., Broquaire M., Colafranceschi C., Thénot J.P. High-performance liquid chromatographic determination of alfuzosin in biological fluids with fluorimetric detection and large-volume injection. J. Chromatogr. 1986; 353: 361-369.
4. McKeage K. and Plosker G. L. Alfuzosin: A Review of the Therapeutic Use of the Prolonged-Release Formulation Given Once Daily in the Management of Benign Prostatic Hyperplasia. Drugs. 2002; 62: 633-653.
5. Krstulovic A.M. and Vende, J.L. Improved performance of the second generation alpha 1-AGP columns: applications to the routine assay of plasma levels of alfuzosin hydrochloride. Chirality 1989; 1: 243-245.
6. Rouchouse A., Manoha M., Durand A., Thénot J.P. Direct high-performance liquid chromatographic determination of the enantiomers of alfuzosin in plasma on a second-generation alpha 1-acid glycoprotein chiral stationary phase. J. Chromatogr. 1990; 506: 601-610.
7. Desager J.P., Harvengt C., Bianchetti G. and Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int. J. Clin. Pharmacol. Ther. Toxicol. 1993; 31: 568-571.
8. Carlucci G, Di-Giuseppe E and Mazzeo P. Determination of alfuzosin in human plasma by high-performance liquid chromatography with column- switching. J. Liq. Chromatogr. 1994; 17: 3989-3997.
9. Yao H., Jin Y., Li J., Zhang Y., Ding X. and Xu S. Determination of alfuzosin in human plasma by RP- HPLC with fluorometric detection. Yaowu Fenxi Zazhi. 2002; 22: 127-129.
10. Li Y., Li K., Wang W., Liu L., Shi A., Hao G. And Sun C. HPLC for plasma concentration of alfuzosin hydrochloride. Zhongguo Yiyuan Yaoxue Zazhi 2000; 20: 344-346.
11. Wiesner J.L., Sutherland F.C.W., Van Essen G.H., Hundt, H.K.L. Swart, K.J. and Hundt, A.F. Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma. J. Chromatogr. B, 2003; 788: 361-368.
12. Mistri H.N., Jangid A.G., Pudage A., Rathod D.M. and Shrivastav P.S. Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective α1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma. J. Chromatogr. B, 2008; 876: 236-244.
13. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Centre for Drug Evaluation and Research, Rockville, MD, 2001, http://www.fda.gov/cder/guidance/4252fnl.pdf.